SIGA Technologies Inc. (SIGA) — Analysis Summary
SIGA Technologies Inc. (SIGA) has a market cap of $258.92M with year-over-year revenue growth of -31.8%. Net margin stands at 24.6%. The stock trades at a P/E ratio of 12.8.
Key Takeaways
- Revenue changed -31.8% year-over-year
- Net margin of 24.6%
- P/E ratio of 12.8
Compared to other companies in the PHARMACEUTICAL PREPARATIONS sector, SIGA posted revenue growth of -31.8% and trades at a P/E of 12.8.
SIGA Technologies Inc. (SIGA)
UPDATED — ET · SOURCE POLYGON
Red Flags & WarningsNo Major Flags
No major credit, margin, or trend red flags were triggered from the latest filings.
SIGA Technologies Inc a commercial-stage pharmaceutical company. The Company sells its product, TPOX oral TPOXX, also known as tecovirimat, Tecovirimat-SIGA, or TEPOXX (tecovirimat) in certain international markets, to the U.S. Government and international governments (including government-affiliated entities). The Company operates in one single operating and reportable segment, which includes all activities related to the sale of the Company's Oral and IV TPOXX as well as research and development services.
Sector
PHARMACEUTICAL PREPARATIONS
Employees
49
Headquarters
NEW YORK, NY
Exchange
XNAS
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Annual Dividend/Share
$0.60
Dividend Yield
17.54%
Dividend History
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.